Onlgyza (saxagliptin), a popular medication for treating type-2 diabetes, has been associated with a potential risk of pancreatic cancer.
In March 2013, the journal Diabetes published a study that found a strong link between Onglyza and pancreatic cancer. In the study, researchers conducted autopsies on 20 people who had diabetes, 8 of whom used an incretin mimetic drug such as Onglyza.
The researchers found that patients who had taken an incretin mimetic to treat their diabetes had pancreases that were 40 percent larger than normal.
These patients also showed a 6-fold increase in the number of beta cells in their pancreases, as well as “eccentric” pre-cancerous cell growth and small tumors called adenomas. While initially benign, adenomas may become malignant and cause pancreatic cancer.
In response to the study published in Diabetes, the FDA released a safety communication in 2013 announcing that the agency was initiating an in-depth investigation into the link between Onglyza and pancreatic cancer.
Pancreatic cancer is one of the deadliest forms of cancer. It can be very difficult to diagnose early, and patients commonly have the disease for several months before they realize it. Consequently, the cancer continues to develop undetected in the pancreas until diseased cells reach the lymph system and bloodstream.
Usually undiagnosed until its third or fourth stages of metastasis, this cancer may have attacked organs in distant parts of the body. The prognosis by then is grim, with only about 25 percent of patients surviving one year after diagnosis and a 5-year survival rate of less than 5 percent.
About Onglyza
Onglyza was developed and marketed by Bristol-Myers Squibb and AstraZeneca, and is prescribed for lowering blood sugar levels in adult patients with type-2 diabetes. Type-2 diabetes affects millions of Americans and their families.
Onglyza, approved for sale in the U.S. in July 2009, works by increasing the pancreas’s insulin production and reducing the amount of sugar that the liver produces when blood sugar levels are too high.
Onglyza belongs to a class of diabetes medications known as incretin mimetics. Other drugs in this class include Byetta, Januvia, Janumet.
Incretin mimetic drugs work by mimicking the incretin hormones produced by the body to stimulate the release of insulin after ingesting food. Together with exercise and healthy eating, these drugs can help lower blood sugar levels in adults with type-2 diabetes.
Onglyza Pancreatic Cancer Lawsuits
In Onglyza pancreatic cancer lawsuits, plaintiffs across the U.S. are claiming that Onglyza’s manufacturers negligently marketed and promoted the drug and failed to adequately test it or warn consumers of the risks of pancreatic cancer.
If you or someone you love has been diagnosed with pancreatic cancer after taking Onglyza or a similar diabetes medication, you may be able to recover compensation for medical expenses, pain and suffering, and additional possible damages through an Onglyza lawsuit.
In general, Onglyza lawsuits are filed individually by each plaintiff and are not class actions.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual Onglyza lawsuit or Ongylyza class action lawsuit is best for you. Hurry — statutes of limitations may apply.
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2015 Top Class Actions® LLC
Various Trademarks held by their respective owners
Get Help – It’s Free
Join a Free Onglyza Lawsuit Investigation
If you or a loved one were injured from Onglyza side effects such as heart failure, thyroid cancer or pancreatic cancer, you may have a legal claim. See if you qualify to pursue compensation and join a free Onglyza lawsuit investigation by submitting your information for a free case evaluation.
An attorney will contact you if you qualify to discuss the details of your potential case.
- First Name*
- Last Name*
- Street Address*
- Apt. #
- City*
- State*
AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict of ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingArmed Forces AmericasArmed Forces EuropeArmed Forces Pacific
- Zip Code*
- Phone*
- Email*
- What year did you/your loved one start taking Onglyza?*
- Which of the following problems did you/your loved one experience after taking Onglyza?*
-
Heart Failure
-
Heart Attack
-
Pancreatic Cancer
-
Thyroid Cancer
-
Death
-
Other (please describe in the additional details box below)
-
- What year were you/your loved one diagnosed with one or more of these problems?*
- ¿Necesita un orador español?
- Yes
- No
- Please enter any additional details you would like the staff reviewing your submission to know.*
- I understand and agree that submitting this form does not create an attorney-client relationship and that the information I submit is not confidential or privileged and may be shared.*
-
Yes
-
-
if(typeof gf_global == ‘undefined’) var gf_global = {“gf_currency_config”:{“name”:”U.S. Dollar”,”symbol_left”:”$”,”symbol_right”:””,”symbol_padding”:””,”thousand_separator”:”,”,”decimal_separator”:”.”,”decimals”:2},”base_url”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms”,”number_formats”:[],”spinnerUrl”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms\/images\/spinner.gif”};jQuery(document).bind(‘gform_post_render’, function(event, formId, currentPage){if(formId == 141) {gformInitChosenFields(‘#input_141_5′,’No results matched’);if(!/(android)/i.test(navigator.userAgent)){jQuery(‘#input_141_7’).mask(‘(999) 999-9999’).bind(‘keypress’, function(e){if(e.which == 13){jQuery(this).blur();} } );}} } );jQuery(document).bind(‘gform_post_conditional_logic’, function(event, formId, fields, isInit){gformInitChosenFields(‘#input_141_5′,’No results matched’);} ); jQuery(document).ready(function(){jQuery(document).trigger(‘gform_post_render’, [141, 1]) } );
The post FDA Investigates Possible Link Between Onglyza and Pancreatic Cancer appeared first on Top Class Actions.
No comments:
Post a Comment